Vaccines

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus-related lower respiratory tract disease in older adults over three seasons.

A single dose of the mRNA-1273.222 vaccine demonstrated strong immune responses against various omicron subvariants and showed a favorable safety profile compared to existing vaccines.

An English modeling study suggests level of protection decreases only very slightly over time and reminds parents to have their children up to date on all vaccinations.

The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.

The federal agency offers guidance for US clinicians and travelers to understand the disease better and employ preventative measures to reduce incidence rates.

The federal agency gave the nod to FluMist nasal spray to allows individuals to administer the vaccine themselves and as a caregivers to others.

The CSL and Arcturus Therapeutics’ vaccine, ARCT-154 (Kostaive), is designed to offer protection against the JN1 strain.

The Phase 1/2 study of VAX-31 demonstrated that the vaccine was well tolerated and elicited strong opsonophagocytic activity immune responses across all 31 evaluated serotypes.

Approved for individuals aged 12 years and older, this vaccine features a monovalent component and replaces the previous Novavax formula.

As National Immunization Awareness Month concludes this August, it is a good time to review and update your vaccination schedules before the fall season begins.

Two recent CDC Morbidity and Mortality Weekly Report (MMWR) studies show stable overall vaccination rates for 2023 but a decline in HPV vaccination rates for certain birth cohorts.

The 2024-2025 season introduces a new vaccine formula with a monovalent component designed to enhance protection against current variants and reduce severe outcomes such as hospitalization and death.

The companies’ study met 1 of their 2 primary immunogenicity objectives.

A new phase 1 clinical trial will determine if vaccine candidate, MPV/S-2P, is safe for humans, and may potentially offer protection not seen before in the first-generation of COVID-19 vaccines.

In this week’s edition of MMWR, the Centers for Disease Control and Prevention reported on the vaccines’ safety profile for each of the FDA approved immunizations and rationale for the recommended age groups.

A single-dose dengue vaccine that is effective across various age groups and independent of prior dengue exposure is essential.

A large English study shows the incidence rates of arterial thromboses and venous thrombotic events decreased after immunization.

A new analysis says if all states imposed such measures it would have saved thousands of lives.

A large study from the Veterans Affairs shows an association between being unvaccinated and a greater incidence rate of Long COVID.

The disconnect between evolving science and medical communication has left people confused about how to interpret public health information, and provided an opportunity for vaccine deniers and politicians to give disinformation on COVID-19.

Emily Hadley highlights study findings showing a higher incidence of Long COVID following initial infections compared to reinfections, particularly during the Omicron period among 3 million patients.

The company acquired rights from CureVac to develop vaccines for influenza and COVID-19 using the mRNA platform.

Paul Radspinner, MBA, president and CEO of FluGen, addresses the safety profile, noting the low adverse event rates highlighting the safety and tolerability of the H3N2 M2SR influenza vaccine.

Adults 65 and older account for 70–85% of annual influenza-related deaths in the USA, underscoring the need for improved vaccine options, as current injectable vaccines show modest efficacy in many seasons.

The Centers for Disease Control and Prevention (CDC) and the National Foundation for Infectious Diseases (NFID) both weigh in on the evolving summer COVID-19 season, and strategies for prevention.

Matthew M Davis, MD, MAPP elaborates on how higher COVID-19 vaccination rates may curb the virus, alleviate childhood asthma symptoms, and protect against other common colds.

Despite initial concerns about vaccine safety, the study of nearly 3000 patients found no elevated risk of preterm birth associated with prenatal vaccination.

The $176 million award is for late-stage development of widespread immunization capability against H5 (avian) influenza, should such vaccines be needed.

Boosted neutralization against variant XBB15 fades within 3 months post-first booster in transplant recipients but improves with a second, hybrid immunity enhances, suggesting 3-6 month boost intervals for solid organ transplant recipients.

Novavax, Inc has unveiled promising results regarding its JN1 COVID-19 vaccine's efficacy against emerging virus variants, including KP2 and KP3.